EUCTR2011-003958-85-GB进行中（未招募）1 期
A Phase II, Single Arm, Investigative Study of IMM-101 in Combination with Radiation Induced Tumour Necrosis in Patients with Previously Treated Colorectal Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Are male or female; aged =18 years.
- •2. Have a histologically confirmed colorectal adenocarcinoma.
- •3. Have documented evidence of disease progression following at least one line of chemotherapy.
- •4. Have no further standard chemotherapy options available or the patient has refused further chemotherapy.
- •5. Have metastatic lesions in at least two sites in the liver (+/- other sites) suitable for bidimensional and volumetric evaluation by CT scan.
- •6. Have WHO performance status of 0-2.
- •7. Have a Cockcroft calculated Glomerular Filtration Rate of > 40mL/min at screening.
- •8. Have a life expectancy, in the opinion of the Investigator, of >3 months from screening.
- •9. Provide written informed consent to participate as shown by a signature and date on the patient's informed consent form (ICF).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 5
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 24
排除标准
- •1. Patient has evidence of central nervous system metastasis.
- •2. Patient has severe, active uncontrolled infection requiring systemic antibiotics, antiviral or antifungal treatments.
- •3. Patient has any previous or concurrent malignancy, except adequately treated carcinoma in situ of the cervix, basal cell carcinoma of the skin and/or non-melanoma skin cancer, or if previous malignancy was more than 5 years earlier and there are no signs of recurrence.
- •4. Patient has serum albumin < 30 g/L at screening.
- •5. Patient has a C-reactive protein (CRP) > 70 mg/L at screening.
- •6. Patient has transaminases (ALT or AST) > 5 X Upper Limit of Normal at screening.
- •7.Patient has a bilirubin level > 2 X Upper Limit of Normal at screening.
- •8. Patient has had radiotherapy in the 12 weeks before screening.
- •9. Patient has used depot corticosteroids in the 6 weeks before screening.
- •10. Patient has had chronic use of any systemic corticosteroids (>10 mg per day of prednisolone or equivalent for a period of 2 weeks or more) and/or immunosuppressant drugs (such as azathioprine, tacrolimus, cyclosporin) within the 2-week period before the first administration of study drug.
- •11. Patient of child-bearing potential who is not using an approved method of birth control (e.g., physical barrier [patient and partner], contraceptive pill or patch, spermicide and barrier, or intrauterine device [IUD]). Those patients that utilise hormonal contraceptives must have used the same method for at least three months before study dosing.
- •Patients of non-child-bearing potential are defined as having 12 month amenorrhoea or are surgically sterile.
- •12. Patient who is pregnant, breast feeding or planning a pregnancy during the course of the study. Where appropriate, a pre-treatment serum pregnancy test measuring human chorionic gonadotrophin (hCG) must be negative.
- •13. Patient has been administered any investigational product in the 3 months before screening.
- •14. Contraindication to CT scan, e.g., allergy to iodine based contrast medium.
- •15. Patient has a surgical or medical condition which, in the judgement of the Investigator, might interfere with the activity of IMM-101, or with the performance of this study.
- •16. Patient has presence of any uncontrolled concomitant disease (e.g., unstable angina pectoris, congestive heart failure, myocardial infarction, cardiac arrhythmias, uncontrolled severe hypertension) which, in the judgement of the Investigator, might interfere with the activity of IMM-101, or with the performance of this study.
- •17. Patient has a history of serious adverse reaction or serious hypersensitivity to any drug that in the opinion of the Investigator may raise a safety concern.
- •18. Patient has had any previous treatment with IMM-101 or related mycobacterial immunotherapy (prior BCG vaccination against TB is allowed).
- •19. Patient is known to have a history of human immunodeficiency virus (HIV) or syphilis, current symptomatic Hepatitis B or C.
- •20. Patient is unable or unwilling to comply with the protocol.
研究者
相似试验
进行中（未招募）
不适用
A Phase II Trial to Evaluate the Activity of Imetelstat (GRN163L) in Patients with Essential Thrombocythemia who Require Cytoreduction and Have Failed or Are Intolerant to Previous Therapy, or who Refuse Standard TherapyMedDRA version: 16.0Level: PTClassification code 10015493Term: Essential thrombocythaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Essential thrombocythemiaEUCTR2010-023076-10-DEGeron Corporation40
进行中（未招募）
1 期
A Phase IV, single group study to evaluate the immunogenicity and safety in UK laboratory workers of a licensed Hib and meningococcal C conjugate combined vaccine (Menitorix) - StaMeInvestigating the immunogenicity and safety of a licensed Hib and meninigococcal C combined conjugate vaccine (Menitorix) in laboratory workers.MedDRA version: 14.0 Level: LLT Classification code 10027276 Term: Meningococcal meningitis System Organ Class: 10021881 - Infections and infestationsEUCTR2006-004302-74-GBHealth Protection Agency
进行中（未招募）
1 期
A Phase IV, single group study to evaluate the immune response to licensed seasonal influenza vaccine and relationship of this to cytomegalovirus-associated immunosenescence in UK older adults aged 50-80 years.EUCTR2006-006563-23-GBHealth Protection Agency
进行中（未招募）
1 期
A Study of IMM 101 in combination with various standard cancer treatments in patients with advanced cancer or cancer which cannot be removed by surgery.Metastatic Cancer or Unresectable CancerMedDRA version: 19.1Level: PTClassification code 10028980Term: NeoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001459-28-GBImmodulon Therapeutics Ltd2
进行中（未招募）
1 期
A phase II study in patients with low and intermediate -1 risk myelodysplastic syndrome while on therapy with deferasirox to investigate the presence of molecular factors in the baseline bone marrow which could predict an hematologic improvement due to therapy with deferasiroxThe study will include two groups of patients with low and intermediate 1 risk myelodysplastic syndrome. One group consists of patients who experience an hematological response while on deferasirox therapy while the other group consists of patients who are non-respondersEUCTR2015-003775-30-BEovartis Pharma NV